CAS 518048-05-0
:Raltegravir
Description:
Raltegravir is an antiretroviral medication primarily used in the treatment of HIV infection. It belongs to a class of drugs known as integrase inhibitors, which work by blocking the integrase enzyme, thereby preventing the integration of viral DNA into the host cell's genome. This action helps to inhibit viral replication. Raltegravir is characterized by its relatively low molecular weight and a specific chemical structure that includes a pyrimidinone core. It is typically administered orally and is known for its favorable pharmacokinetic profile, including good bioavailability and a manageable side effect profile. Common side effects may include gastrointestinal disturbances and potential effects on liver function. Raltegravir is often used in combination with other antiretroviral agents to enhance treatment efficacy and reduce the risk of resistance development. Its introduction has significantly improved treatment options for individuals living with HIV, contributing to better management of the disease and improved quality of life for patients.
Formula:C20H21FN6O5
InChI:InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)
InChI key:InChIKey=CZFFBEXEKNGXKS-UHFFFAOYSA-N
SMILES:C(NC(=O)C1=NN=C(C)O1)(C)(C)C2=NC(C(NCC3=CC=C(F)C=C3)=O)=C(O)C(=O)N2C
Synonyms:- 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-
- 5-Hydroxy-2-[1-[[(5-Methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]-1-methylethyl]-N-(4-fluorobenzyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide
- N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}ethyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide
- N-[(4-Fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxamide
- Raltegravir
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 10 products.
Raltegravir
CAS:Formula:C20H21FN6O5Purity:≥ 99.0%Color and Shape:White to off-white crystalline powderMolecular weight:444.42Raltegravir
CAS:<p>Raltegravir (MK-0518) is a pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV</p>Formula:C20H21FN6O5Purity:99.86% - >99.99%Color and Shape:SolidMolecular weight:444.42Raltegravir
CAS:Controlled Product<p>Applications Raltegravir (MK-0518) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN.<br>References Hare, S., et al.: Proc. Natl. Acad. Sci. U. S. A., 107, 20057 (2010); Hicks, C., et al.: Clin. Infect. Dis., 48, 931 (2009); Moss, D., et al.: Antimicrob. Agents Chemother., 56, 3020 (2012); Hare, S., et al.: Mol. Pharmacol., 80, 565 (2011)<br></p>Formula:C20H21FN6O5Color and Shape:NeatMolecular weight:444.42Raltegravir
CAS:<p>Raltegravir is an antiretroviral agent, which is a synthetic integrase inhibitor sourced from pharmaceutical research. Its mode of action involves the inhibition of the HIV-1 integrase enzyme, which is essential for the viral replication process. By blocking the strand transfer step of the integration of viral DNA into the host cell genome, Raltegravir prevents the proliferation of the virus within the host.</p>Formula:C20H21FN6O5Purity:Min. 98 Area-%Color and Shape:White Off-White PowderMolecular weight:444.42 g/molRaltegravir - Bio-X ™
CAS:<p>Raltegravir is an antiretroviral agent used for the treatment of HIV infections in conjunction with other antiretrovirals. It inhibits the activity of HIV-1 integrase, which impedes the insertion of HIV-1 DNA into the host cell genome. Raltegravir also inhibits resistant mutants of HIV-1 that are associated with disease activity and progression.</p>Formula:C20H21FN6O5Purity:Min. 98 Area-%Color and Shape:PowderMolecular weight:444.42 g/mol
